Day Traders Tag icon

×
On Friday, Johnson & Johnson (NYSE:JNJ) announced that it would implement significant changes to offering 340B pricing for its popular drugs, Stelara and Xarelto. Stelara (ustekinumab) is indicated for moderate to severe psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Xarelto (rivaroxaban) is a blood thinner that treats and helps prevent blood clots related to certain conditions involving the heart and blood vessels. Also Read: Medicare Costs For Johnson & Johnson’s Psoriasis Drug Stelara Double When Obtained at Pharmacies. Beginning October 15, disproportionate share hospitals (DSHs) participating in the 340B Drug Pricing Program must buy these drugs at full price and submit data to Johnson ...


In The news